New Mantle Cell Treatment on US FDA Fast Track
The US Food and Drug Administration (FDA) has granted the drug VELCADE (bortezomib) fast track designation for relapsed and refractory mantle cell lymphoma (MCL). MCL is an aggressive form of non-Hodgkin's lymphoma (NHL) which accounts for approximately six percent of all lymphomas. Currently, VELCADE is being evaluated as a single agent in a multicenter Phase II clinical trial for the treatment of mantle cell lymphoma. It is expected that interim data from the trial will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2005.